Last reviewed · How we verify
DWP712
At a glance
| Generic name | DWP712 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines (PHASE3)
- Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWP712 CI brief — competitive landscape report
- DWP712 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI